

# Yutaka Yasui

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5323483/publications.pdf>

Version: 2024-02-01

82  
papers

2,319  
citations

186265  
28  
h-index

233421  
45  
g-index

83  
all docs

83  
docs citations

83  
times ranked

2940  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan. Digestive Diseases, 2022, 40, 479-488.  | 1.9 | 1         |
| 2  | Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 1171-1173.e2.   | 4.4 | 22        |
| 3  | Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. Investigational New Drugs, 2022, 40, 392-402.  | 2.6 | 36        |
| 4  | Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatology Communications, 2022, 6, 461-472.  | 4.3 | 10        |
| 5  | Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Alimentary Pharmacology and Therapeutics, 2022, 55, 292-301.  | 3.7 | 38        |
| 6  | Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma. PLoS ONE, 2022, 17, e0265235.   | 2.5 | 4         |
| 7  | A validation study of after direct-acting antiviral recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response. JGH Open, 2022, 6, 20-28. | 1.6 | 4         |
| 8  | Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment. JGH Open, 2022, 6, 301-308.   | 1.6 | 7         |
| 9  | Validation of magnetic resonance elastography plus FIB-4 for significant fibrosis in nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2022, , .   | 2.8 | 1         |
| 10 | <scp>General evaluation score</scp> for predicting the development of <scp>hepatocellular carcinoma</scp> in patients with advanced liver fibrosis associated with <scp>hepatitis C virus</scp> genotype 1 or 2 after <scp>direct-acting antiviral</scp> therapy. JGH Open, 2022, 6, 487-495.                  | 1.6 | 0         |
| 11 | Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers, 2022, 14, 2975.   | 3.7 | 5         |
| 12 | A Comparison of Late Mortality Among Survivors of Childhood Cancer in the United States and United Kingdom. Journal of the National Cancer Institute, 2021, 113, 562-571.  | 6.3 | 14        |
| 13 | Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antiviral treatment in patients with chronic hepatitis C. Journal of Medical Virology, 2021, 93, 3744-3751.  | 5.0 | 8         |
| 14 | Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. Journal of Viral Hepatitis, 2021, 28, 787-794.   | 2.0 | 7         |
| 15 | Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. Clinical Infectious Diseases, 2021, 73, e3349-e3354.   | 5.8 | 21        |
| 16 | Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2943-2951.  | 2.8 | 11        |
| 17 | Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade. Hepatology Research, 2021, 51, 902-908.  | 3.4 | 11        |
| 18 | Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. Journal of Medical Ultrasonics (2001), 2021, 48, 481-487.   | 1.3 | 11        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2960-2966.  | 2.8 | 36        |
| 20 | Rethinking Success in Pediatric Oncology: Beyond 5-Year Survival. <i>Journal of Clinical Oncology</i> , 2021, 39, 2227-2231.   | 1.6 | 34        |
| 21 | Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. <i>JGH Open</i> , 2021, 5, 1085-1091.  | 1.6 | 5         |
| 22 | Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. <i>International Journal of Molecular Sciences</i> , 2021, 22, 40.                       | 4.1 | 8         |
| 23 | Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. <i>Hepatology Research</i> , 2020, 50, 137-143.  | 3.4 | 19        |
| 24 | Hepatitis B virus-related hepatocellular carcinoma in young adults: Efficacy of nationwide selective vaccination. <i>Hepatology Research</i> , 2020, 50, 182-189.  | 3.4 | 8         |
| 25 | Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir. <i>JGH Open</i> , 2020, 4, 429-432.   | 1.6 | 11        |
| 26 | Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. <i>Hepatology Research</i> , 2020, 50, 1375-1385.   | 3.4 | 22        |
| 27 | Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy. <i>Scientific Reports</i> , 2020, 10, 13566.  | 3.3 | 6         |
| 28 | Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. <i>JGH Open</i> , 2020, 4, 1183-1190.         | 1.6 | 6         |
| 29 | Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not Î±-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3640.                 | 4.1 | 5         |
| 30 | Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. <i>Hepatology Research</i> , 2020, 50, 996-999.   | 3.4 | 5         |
| 31 | Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1595-1601.               | 2.8 | 18        |
| 32 | Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1355-1358.                                    | 5.0 | 16        |
| 33 | Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients. <i>Diagnostics</i> , 2020, 10, 173.          | 2.6 | 8         |
| 34 | Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0231828. | 2.5 | 42        |
| 35 | Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2019, 9, 10109.   | 3.3 | 24        |
| 36 | Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. <i>Cancers</i> , 2019, 11, 1517.     | 3.7 | 30        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1256.   | 3.7 | 17        |
| 38 | Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2004-2010.  | 2.8 | 48        |
| 39 | Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2616-2618.  | 4.4 | 17        |
| 40 | Imaging Findings of Hepatocellular Carcinoma that Developed after HCV Eradication with Direct-Acting Antivirals. <i>Acta Hepatologica Japonica</i> , 2019, 60, 46-48.   | 0.1 | 0         |
| 41 | Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2019, 26, 893-899.   | 2.0 | 25        |
| 42 | Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. <i>PLoS ONE</i> , 2019, 14, e0211122.   | 2.5 | 23        |
| 43 | Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. <i>Hepatology Research</i> , 2019, 49, 33-41.  | 3.4 | 22        |
| 44 | Up to seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. <i>Hepatology Research</i> , 2018, 48, 442-450.  | 3.4 | 49        |
| 45 | Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. <i>Hepatology Research</i> , 2018, 48, 1131-1139.   | 3.4 | 40        |
| 46 | Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. <i>PLoS ONE</i> , 2018, 13, e0198812.  | 2.5 | 51        |
| 47 | Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2017, 7, 244.  | 3.3 | 14        |
| 48 | Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. <i>PLoS ONE</i> , 2017, 12, e0174649.  | 2.5 | 24        |
| 49 | Pretreatment Gastric Lavage Reduces Postoperative Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms. <i>PLoS ONE</i> , 2016, 11, e0149235.  | 2.5 | 5         |
| 50 | Four cases with advanced hepatocellular carcinoma who achieved long survival, after surgical resection following to down-staging therapies. <i>Acta Hepatologica Japonica</i> , 2016, 57, 649-655.  | 0.1 | 1         |
| 51 | Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. <i>Cancer Medicine</i> , 2016, 5, 3111-3120. | 2.8 | 17        |
| 52 | Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. <i>Liver Cancer</i> , 2016, 5, 257-268.  | 7.7 | 16        |
| 53 | Urinary excretion of the water channel aquaporin-2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. <i>Journal of Gastroenterology</i> , 2016, 51, 620-627.  | 5.1 | 36        |
| 54 | Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0154558.  | 2.5 | 34        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. <i>Hepatology Research</i> , 2015, 45, E115-21.          | 3.4 | 37        |
| 56 | <i>Wisteria floribunda</i> agglutinin positive human Mac-2 binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. <i>Hepatology Research</i> , 2015, 45, E82-8.          | 3.4 | 55        |
| 57 | Non-alcoholic fatty liver disease fibrosis score and <scp>FIB</scp>-4 scoring system could identify patients at risk of systemic complications. <i>Hepatology Research</i> , 2015, 45, 667-675.                           | 3.4 | 26        |
| 58 | Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. <i>PLoS ONE</i> , 2015, 10, e0137351. | 2.5 | 22        |
| 59 | Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. <i>PLoS ONE</i> , 2015, 10, e0138060.   | 2.5 | 18        |
| 60 | L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1540-1543.  | 4.4 | 53        |
| 61 | Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. <i>Cancer</i> , 2014, 120, 229-237.                       | 4.1 | 57        |
| 62 | Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy. <i>Hepatology Research</i> , 2014, 44, 319-326.  | 3.4 | 12        |
| 63 | Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2014, 49, 1152-1162.   | 5.1 | 28        |
| 64 | Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. <i>Journal of Gastroenterology</i> , 2014, 49, 1495-1503.                                    | 5.1 | 44        |
| 65 | Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. <i>Liver Transplantation</i> , 2014, 20, 291-297.                           | 2.4 | 33        |
| 66 | Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis <scp>C</scp> patients. <i>Hepatology Research</i> , 2014, 44, 720-727.       | 3.4 | 22        |
| 67 | Reduced Organic Anion Transporter Expression Is a Risk Factor for Hepatocellular Carcinoma in Chronic Hepatitis C Patients: A Propensity Score Matching Study. <i>Oncology</i> , 2014, 86, 53-62.                         | 1.9 | 18        |
| 68 | Î±-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. <i>Hepatology</i> , 2013, 58, 1253-1262.  | 7.3 | 227       |
| 69 | Two cases of acute liver failure caused by hepatitis A which were negative for serum IgM-HA antibody at the early stage of the onset. <i>Acta Hepatologica Japonica</i> , 2013, 54, 553-558.                              | 0.1 | 0         |
| 70 | Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 249.  | 3.3 | 44        |
| 71 | Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. <i>Hepatology</i> , 2012, 55, 20-29.   | 7.3 | 54        |
| 72 | Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy. <i>Hepatology Research</i> , 2011, 41, 217-224.         | 3.4 | 4         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , 2011, 16, 685-694.  | 1.0 | 35        |
| 74 | Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. <i>Oncology</i> , 2011, 80, 278-288.   | 1.9 | 67        |
| 75 | Early Decrease in $\alpha$ -Fetoprotein, but Not Des- $\gamma$ -Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 251-258.  | 1.9 | 78        |
| 76 | Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis. <i>Acta Hepatologica Japonica</i> , 2011, 52, 325-326.   | 0.1 | 0         |
| 77 | Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 518-527.  | 7.3 | 265       |
| 78 | Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2010, 51, 403-404.  | 0.1 | 1         |
| 79 | A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. <i>Hepatology Research</i> , 2010, 40, 251-260.  | 3.4 | 58        |
| 80 | Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. <i>Hepatology Research</i> , 2010, 40, 870-877. | 3.4 | 65        |
| 81 | Potential Relevance of Cytoplasmic Viral Sensors and Related Regulators Involving Innate Immunity in Antiviral Response. <i>Gastroenterology</i> , 2008, 134, 1396-1405.   | 1.3 | 39        |
| 82 | Two cases of hepatic angiomyolipoma with different ultrasonographic and radiographic findings. <i>Acta Hepatologica Japonica</i> , 2008, 49, 440-448.  | 0.1 | 2         |